Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502924 · ClinicalTrials.gov registry record · NA
Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health
A NA study, sponsored by Lindenwood University.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT07502924 is a NA study that is actively recruiting participants, run by Lindenwood University. The registered enrollment target is 70 participants.
The verdict
NCT07502924, a NA study, is actively recruiting participants, sponsored by Lindenwood University.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group trial lasting 8 weeks. Participants will be assigned to receive either placebo, 150 mg GG, or 300 mg GG daily. Outcome measures will be assessed at baseline, week 4, and week 8 and include maximal strength (1RM bench press and leg press), fat-free mass, muscular endurance, aerobic capacity (VO2peak), and circulating biomarkers related to metabolism and health.
Interventions
- DIETARY_SUPPLEMENT Dietary Supplement - Placebo
- DIETARY_SUPPLEMENT Geranylgeraniol (150 mg)
- DIETARY_SUPPLEMENT Geranylgeraniol (300 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502924
The ClinicalTrials.gov registry entry for NCT07502924 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindenwood University, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dietary Supplement - Placebo is the first listed.
NCT07502924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502924 about?
NCT07502924 is a clinical study titled "Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health". This study will evaluate the effects of daily geranylgeraniol (GG) supplementation on muscular strength, body composition, and aerobic capacity in healthy, physically active men and women. Approximately 60 participants aged 30-60 years will be enrolled in a randomized, double-blind, placebo-controll...
What is the current status of trial NCT07502924?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-03-03. Estimated completion is 2026-08-01.
What interventions are being tested in trial NCT07502924?
The interventions under investigation include: Dietary Supplement - Placebo (DIETARY_SUPPLEMENT), Geranylgeraniol (150 mg) (DIETARY_SUPPLEMENT), Geranylgeraniol (300 mg) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07502924?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.